An Open-Label Prophylaxis Study of Lithium Plus Extended-Release Carbamazepine (ERC-CBZ) Combination for Rapid Cycling Bipolar Disorder

| September 1, 2017 | 0 Comments

by Sriram Ramaswamy, MD; David Driscoll, PhD; and Lynette M. Smith, PhD

Dr. Ramaswamy is with the Department of Psychiatry, Creighton University School of Medicine, Omaha, Nebraska, and the VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska. Dr. Driscoll is with the VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska. Dr. Smith is with the College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska.

Funding/financial disclosures: This work was supported by an investigator-initiated grant from Shire Pharmaceuticals.

Keywords: carbamazepine, lithium, rapid cycling, bipolar disorder

The content you are trying to view is restricted to registered members only.
Membership to Innovations in Clinical Neuroscience is free, so please consider becoming a member today.
Thank you
ICNS Online Editor
Please Login or Register for access.

Tags: , , ,

Category: Letters to the Editor, Past Articles

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.